Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy. However, despite the benefits of this therapy, ...
Jun 15, 2022
0
84
Researchers from Boston University School of Medicine (BUSM) have discovered that the protein BRD4 could be an important new target to prevent castration-resistant prostate cancer metastases.
Jul 21, 2020
0
163
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
Like the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient's metastatic prostate cancer. PSMA is a protein on the cell surface ...
Apr 10, 2023
0
88
A trio of drugs could delay the progression of metastatic castration-resistant prostate cancer.
Nov 3, 2021
0
12
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29
(HealthDay)—Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. ...
Feb 19, 2019
0
1
The HSD3B1 gene could hold clues for predicting and treating endometrial cancer, according to a novel finding from the Cleveland Clinic's Lerner Research Institute.
Sep 12, 2022
0
48
A new prostate cancer therapy in clinical trials could treat patients resistant to treatment through targeting the disease on a molecular level, based on new Cleveland Clinic research.
Jan 17, 2023
0
29
The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant ...
Jun 7, 2023
0
2
